A retrospective study for Entecavir (Runzhong) versus Entecavir (Baraclude) in the treatment of patients with chronic hepatitis B before the implementation of the '4+7' urban consumption procurement policy

Real-World Research on the Efficacy and Safety Evaluation of Chinese Medicines with Volume Purchase

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900023944

Enrollment

Unknown

Registered

2019-06-19

Start date

2019-06-20

Completion date

Unknown

Last updated

2019-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis B

Interventions

Cohort 1:entecavir (Runzhong)

Cohort 2:entecavir (Boluding)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Comply with the diagnostic criteria for chronic hepatitis B and the initial antiviral treatment standard in the Guidelines for Prevention and Treatment of Chronic Hepatitis B (2015 Update); 2. Aged = 18 years; 3. No other varieties of antiviral Drug wihin 12 weeks; 4. Entecavir dose of 0.5mg fasting orally once a day.

Exclusion criteria

Exclusion criteria: 1. Combined with other types of liver disease, HIV, liver cancer or decompensated liver disease patients; 2. Taking immunosuppressive agents or glucocorticoids within 24 weeks.

Design outcomes

Primary

Measure	Time frame
efficacy, safety and cost (economy);	—

Contacts

Public ContactZhao Yanling

The Fifth Medical Center of the PLA General Hospital

zhaoyl2855@126.com+86 13681208998

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026